Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 18;17(1):553.
doi: 10.1186/s12885-017-3541-9.

Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients

Dongtai Chen  1 , Yonghua Chen  1 , Yan Yan  2 , Jiahao Pan  1 , Wei Xing  1 , Qiang Li  1 , Weian Zeng  3
Affiliations

Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients

Dongtai Chen et al. BMC Cancer. .

Abstract

Background: Opioid receptors have become increasingly implicated in cancer progression and long-term patient outcomes. However, the expression and significance of the κ-opioid receptor (KOR) in hepatocellular carcinoma (HCC) remain unclear.

Methods: In this study, KOR mRNA expression was analysed by real-time quantitative PCR in 64 pairs of HCC tumour tissues and adjacent non-tumour tissues, and KOR protein expression was analysed by immunohistochemistry in 174 HCC patients. We investigated the correlation between KOR expression and clinicopathological parameters to illustrate the potential prognostic significance of KOR expression in HCC.

Results: KOR mRNA expression was significantly down-regulated in 79.69% (51 of 64) of the HCC tumour samples, and KOR expression in tumour tissue was significantly lower than that in adjacent non-tumour tissues (P < 0.001). ROC curve analysis showed that KOR mRNA expression yielded AUC of 0.745, for the detection of HCC patients. Low KOR mRNA expression in HCC was correlated with aggressive clinicopathological parameters, such as tumour size (P = 0.015), differentiation grade (P = 0.011), and TNM stage (P = 0.021). Moreover, down-regulation of KOR protein expression in HCC tissues was detected in 174 HCC patients. Similarly, negative KOR protein expression was significantly correlated with aggressive clinicopathological features, such as tumour size (P = 0.002), vascular invasion (P = 0.003), differentiation grade (P = 0.026), and TNM stage (P = 0.030). Furthermore, Kaplan-Meier survival analysis demonstrated that down-regulation of KOR in HCC indicated poor prognosis. KOR deficiency (KORT < N) was correlated to a shorter survival rate and an increased recurrence (both P < 0.001). In univariate and multivariate survival analyses, KOR was identified as a promising independent risk factor for both overall survival (OS, both P < 0.001) and recurrence-free survival (RFS, both P < 0.001).

Conclusions: Down-regulation of KOR in HCC tumour tissues has a strong association with poor prognosis and KOR might be a potential tumour suppressor.

Keywords: Hepatocellular carcinoma; Prognosis; Tumour suppressor; κ-opioid receptor.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by Committee for Ethical Review of Research at Sun Yat-sen University Cancer Center. All patients were informed of the analyses and provided written consent for the use of existing tissue samples in the present study. For those survival data were followed up via outpatient visit, written informed consents were obtained. Part of the survival data were obtained thorough telephone follow-up, the written informed consent could not be available due to the long journey from their resident to our hospital. Under these conditions, only verbal informed consents were obtained from these subjects or their legal guardians.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Down-regulation of KOR mRNA in HCC. a KOR mRNA expression in 64 paired HCC tumour tissues (T) and corresponding non-tumour tissues (N). The data revealed that down-regulation of KOR was detected in 79.69% (51 of 64) of HCC samples. b Relative expression levels of KOR in tumour tissues are significantly lower than in corresponding non-tumour tissues (P < 0.001). c ROC curve was constructed according to KOR mRNA expression in HCC and adjacent non-tumour tissues
Fig. 2
Fig. 2
Down-regulation of KOR protein in HCC. a Representative immunohistochemical staining of KOR protein expression in 174 HCC tissue samples (magnification ×200). Absent or weak staining was defined as negative expression, while moderate or strong staining was defined as positive expression. b The presence of KOR staining in HCC tissues and corresponding non-tumour tissues. c, d Kaplan-Meier analysis for overall survival (OS) and recurrence-free survival (RFS) of 174 HCC patients in correlation with KOR expression. The OS and RFS rates were significantly decreased in KOR-negative HCC patients compared with those in the KOR-positive group (both P < 0.001). The duplicated images in Figs. 2, 3 and Additional file 1: Figure S1 represent the same experiment
Fig. 3
Fig. 3
Down-regulation of KOR correlates with poor prognosis in HCC patients. a Representative immunostaining images of KOR loss/gain/retain cases in HCC tumour tissues and adjacent non-tumour tissues (magnification ×200). b Kaplan-Meier curves for OS and RFS according to KOR expression and KOR loss/gain/retain in the validation cohort. The duplicated images in Figs. 2, 3 and Additional file 1: Figure S1 represent the same experiment
Fig. 4
Fig. 4
KOR-positive HCC patients in different subgroups showed a better OS than did KOR-negative HCC patients. a The cohort was classified into 2 groups based on AFP levels with a cut-off point of 20 ng/ml: AFP ≤ 20 ng/ml and AFP > 20 ng/ml; b The cohort was classified into 2 groups based on tumour size with a cut-off point of 5 cm: Tumour size ≤5 cm and Tumour size >5 cm; c The cohort was classified into 2 groups based on differentiation grade: Differentiation grade I/II and Differentiation grade III/IV; d The cohort was classified into 2 groups based on TNM stage: TNM stage I and TNM stage II/III
Fig. 5
Fig. 5
KOR-positive HCC patients in different subgroups showed a better RFS than the KOR-negative HCC patients. a The cohort was classified into 2 groups based on AFP levels with a cut-off point of 20 ng/ml: AFP ≤ 20 ng/ml and AFP > 20 ng/ml; b The cohort was classified into 2 groups based on tumour size with a cut-off point of 5 cm: Tumour size ≤5 cm and Tumour size >5 cm; c The cohort was classified into 2 groups based on differentiation grade: Differentiation grade I/II and Differentiation grade III/IV; d The cohort was classified into 2 groups based on TNM stage: TNM stage I and TNM stage II/III
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576. doi: 10.1053/j.gastro.2007.04.061. - DOI - PubMed
    1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122(6):1609–1619. doi: 10.1053/gast.2002.33411. - DOI - PubMed
    1. Cao LH, Li HT, Lin WQ, Tan HY, Xie L, Zhong ZJ, Zhou JH. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016;6:18706. doi: 10.1038/srep18706. - DOI - PMC - PubMed
    1. Wang K, Qu X, Wang Y, Shen H, Liu Q, Du J. Effect of mu agonists on long-term survival and recurrence in nonsmall cell lung cancer patients. Medicine. 2015;94(33):e1333. doi: 10.1097/MD.0000000000001333. - DOI - PMC - PubMed

MeSH terms